Business
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentationRASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug AdministrationAACR 2026 presentations reinforce the breadth and strength of company’s RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibitionSt
About this update from Revolution Medicines, Inc.
[{"type":"image","alt":"Revolution Medicines, Inc.","displaySize":"","headline":null,"caption":"Revolution Medicines, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/5fd0263e2225a1c8e4ed2273768d4bce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rZNLi5mJW78ZE0xMtIm2pA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/5fd0263e2225a1c8e4ed2273768d4bce","width":300,"height":100},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/rZNLi5mJW78ZE0xMtIm2pA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/5fd0263e2225a1c8e4ed2273768d4bce","width":300,"height":100}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation","length":211,"tagName":"p"}]},{"val":[{"type":"text","content":"RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administration","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"AACR 2026 presentations reinforce the breadth and strength of company’s RAS(ON) portfolio, highlighting continued progress and novel approaches to RAS(ON) inhibition","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened financial position with financings totaling $2.2 billion in gross proceeds","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":653,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2026, and provided an update on corporate progress.","length":328,"tagName":"p"},{"type":"text","content":"“Last month we reported positive results from the RASolute 302 trial of daraxonrasib, demonstrating an unprecedented improvement in overall survival in pat...